Jinyu Bio-technology Second Quarter 2024 Earnings: Revenues Disappoint

Simply Wall St · 09/01 02:24

Jinyu Bio-technology (SHSE:600201) Second Quarter 2024 Results

Key Financial Results

  • Revenue: CN¥263.8m (down 18% from 2Q 2023).
  • Net income: CN¥17.3m (down 38% from 2Q 2023).
  • Profit margin: 6.6% (down from 8.6% in 2Q 2023). The decrease in margin was driven by lower revenue.
  • EPS: CN¥0.015 (down from CN¥0.024 in 2Q 2023).
earnings-and-revenue-growth
SHSE:600201 Earnings and Revenue Growth September 1st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Jinyu Bio-technology Earnings Insights

Looking ahead, revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Biotechs industry in China.

Performance of the Chinese Biotechs industry.

The company's shares are up 4.3% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 2 warning signs for Jinyu Bio-technology you should know about.